Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development
暂无分享,去创建一个
[1] O. Jensen. Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. , 2004, Current opinion in chemical biology.
[2] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[3] M. Danhof,et al. Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers , 2005, Pharmaceutical Research.
[4] Paul J. Williams,et al. Pharmacometrics: Impacting Drug Development and Pharmacotherapy , 2006 .
[5] M. Danhof,et al. 5.38 – Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling for the Prediction of In Vivo Drug Concentration–Effect Relationships – Application in Drug Candidate Selection and Lead Optimization , 2007 .
[6] Steven W. Martin,et al. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. , 2007, Drug discovery today.
[7] Ene I. Ette,et al. Pharmacometrics : the science of quantitative pharmacology , 2007 .
[8] Marc Pfister,et al. Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development , 2008, The AAPS Journal.
[9] H. Lowman,et al. Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody , 2008, The AAPS Journal.
[10] Adam Cohen,et al. Pharmacokinetic and Pharmacodynamic Data to be Derived from Early-Phase Drug Development , 2008, Clinical pharmacokinetics.
[11] William J Jusko,et al. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. , 2009, Drug metabolism and pharmacokinetics.
[12] Lawrence J Lesko,et al. Quantitative disease, drug, and trial models. , 2009, Annual review of pharmacology and toxicology.
[13] Meindert Danhof,et al. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. , 2009, Drug metabolism and pharmacokinetics.
[14] T. Kenakin. Cellular assays as portals to seven-transmembrane receptor-based drug discovery , 2009, Nature Reviews Drug Discovery.
[15] Johan Gabrielsson,et al. Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. , 2009, Future medicinal chemistry.
[16] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[17] Johan Gabrielsson,et al. Optimising in vivo pharmacology studies--Practical PKPD considerations. , 2010, Journal of pharmacological and toxicological methods.
[18] N. Benson,et al. Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent. , 2010, British journal of clinical pharmacology.
[19] Maciej Swat,et al. What it takes to understand and cure a living system: computational systems biology and a systems biology-driven pharmacokinetics–pharmacodynamics platform , 2011, Interface Focus.
[20] D. Noble,et al. Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.
[21] Päivi Heikkilä,et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.
[22] Jan van den Berg,et al. Systems Biology and Pharmacology , 2010, Clinical pharmacology and therapeutics.
[23] D. Howells,et al. Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.
[24] Michael Rowley,et al. Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. , 2011, Current topics in medicinal chemistry.
[25] Gianne Derks,et al. Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. , 2011, Journal of theoretical biology.